Title: Sustained Release of a Peptide-Based Matrix Metalloproteinase-2 Inhibitor to Attenuate Adverse Cardiac Remodeling and Improve Cardiac Function Following Myocardial Infarction.
Authors: Fan, Zhaobo; Fu, Minghuan; Xu, Zhaobin; Zhang, Bo; Li, Zhihong; Li, Haichang; Zhou, Xinyu; Liu, Xuanyou; Duan, Yunyan; Lin, Pei-Hui; Duann, Pu; Xie, Xiaoyun; Ma, Jianjie; Liu, Zhenguo; Guan, Jianjun
Published In Biomacromolecules, (2017 Sep 11)
Abstract: Following myocardial infarction (MI), degradation of extracellular matrix (ECM) by upregulated matrix metalloproteinases (MMPs) especially MMP-2 decreases tissue mechanical properties, leading to cardiac function deterioration. Attenuation of cardiac ECM degradation at the early stage of MI has the potential to preserve tissue mechanical properties, resulting in cardiac function increase. Yet the strategy for efficiently preventing cardiac ECM degradation remains to be established. Current preclinical approaches have shown limited efficacy because of low drug dosage allocated to the heart tissue, dose-limiting side effects, and cardiac fibrosis. To address these limitations, we have developed a MMP-2 inhibitor delivery system that can be specifically delivered into infarcted hearts at early stage of MI to efficiently prevent MMP-2-mediated ECM degradation. The system was based on an injectable, degradable, fast gelation, and thermosensitive hydrogel, and a MMP-2 specific inhibitor, peptide CTTHWGFTLC (CTT). The use of fast gelation hydrogel allowed to completely retain CTT in the heart tissue. The system was able to release low molecular weight CTT over 4 weeks possibly due to the strong hydrogen bonding between the hydrogel and CTT. The release kinetics was modulated by amount of CTT loaded into the hydrogel, and using chondroitin sulfate and heparin that can interact with CTT and the hydrogel. Both glycosaminoglycans augmented CTT release, while heparin more greatly accelerated the release. After it was injected into the infarcted hearts for 4 weeks, the released CTT efficiently prevented cardiac ECM degradation as it not only increased tissue thickness but also preserved collagen composition similar to that in the normal heart tissue. In addition, the delivery system significantly improved cardiac function. Importantly, the delivery system did not induce cardiac fibrosis. These results demonstrate that the developed MMP-2 inhibitor delivery system has potential to efficiently reduce adverse myocardial remodeling and improve cardiac function.
PubMed ID: 28731675
MeSH Terms: Animals; Chondroitin Sulfates/chemistry; Drug Carriers/adverse effects; Drug Carriers/chemical synthesis*; Drug Carriers/chemistry; Drug Liberation*; Extracellular Matrix/drug effects; Extracellular Matrix/metabolism; Heparin/chemistry; Humans; Hydrogels/adverse effects; Hydrogels/chemical synthesis*; Hydrogels/chemistry; Male; Matrix Metalloproteinase 2/metabolism; Matrix Metalloproteinase Inhibitors/administration & dosage; Matrix Metalloproteinase Inhibitors/pharmacokinetics*; Matrix Metalloproteinase Inhibitors/therapeutic use; Myocardial Infarction/drug therapy*; Myocytes, Cardiac/drug effects; Myocytes, Cardiac/metabolism; Peptides, Cyclic/administration & dosage; Peptides, Cyclic/pharmacokinetics*; Peptides, Cyclic/therapeutic use; Rats; Rats, Sprague-Dawley